5-[(E)-2-{4-[(2-carboxyethyl)carbamoyl]-2-[(E)-2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl]phenyl}diazen-1-yl]-2-hydroxybenzoic acid

• ChemBase编号: 163734
• 分子式: C27H24N6O9
• 平均质量: 576.51426
• 单一同位素质量: 576.16047638
• SMILES: c1cc(c(cc1/N=N/c1c(cc(cc1)C(=O)NCCC(=O)O)/N=N/c1ccc(cc1)C(=O)NCCC(=O)O)C(=O)O)O
• Canonical SMILES: OC(=O)CCNC(=O)c1ccc(cc1)/N=N/c1cc(ccc1/N=N/c1ccc(c(c1)C(=O)O)O)C(=O)NCCC(=O)O
• InChI: InChI=1S/C27H24N6O9/c34-22-8-6-18(14-19(22)27(41)42)31-32-20-7-3-16(26(40)29-12-10-24(37)38)13-21(20)33-30-17-4-1-15(2-5-17)25(39)28-11-9-23(35)36/h1-8,13-14,34H,9-12H2,(H,28,39)(H,29,40)(H,35,36)(H,37,38)(H,41,42)/b32-31+,33-30+
• InChIKey: IBCQZTYNNGNNDJ-HIPRBATPSA-N

名称和登记号

名称

• IUPAC标准名: 5-[(E)-2-{4-[(2-carboxyethyl)carbamoyl]-2-[(E)-2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl]phenyl}diazen-1-yl]-2-hydroxybenzoic acid
• IUPAC传统名: 5-[(E)-2-{4-[(2-carboxyethyl)carbamoyl]-2-[(E)-2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl]phenyl}diazen-1-yl]-2-hydroxybenzoic acid
• 别名: 5-[(1E)-2-[2-[(1E)-2-[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]diazenyl]-4-[[(2-carboxyethyl)amino]carbonyl]phenyl]diazenyl]-2-hydroxybenzoic Acid; (E,E)-5-[[2-[4-(2-Carboxyethylcarbamoyl)phenylazo]-4-(2-carboxyethylcarbamoyl)]phenylazo]salicylic Acid; Balsalazide USP Impurity 3; 2'-[(1E)-2-[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]diazenyl] Balsalazide

登记号

• PubChem SID: 162257869
• PubChem CID: 71314536

理论计算性质

• Acid pKa: 2.797714
• 质子受体: 13
• 质子供体: 6
• LogD (pH = 5.5): -2.1469486
• LogD (pH = 7.4): -5.8825765
• Log P: 4.367676
• 摩尔折射率: 153.4513 cm^3
• 极化性: 53.75433 Å^3
• 极化表面积: 239.77 Å^2
• 可自由旋转的化学键: 13
• 里宾斯基五规则: false

详细说明

Toronto Research Chemicals - C178015

An impurity of the anti-inflammatory drug Balsalazide (B116300).